Precision medicine is becoming increasingly important for advanced cancer patients. Certain therapies provide better patient outcomes and fewer side effects than broad-based chemotherapy. But an individual’s response to a given treatment often depends on the genomic profile of their tumor.
For oncologists, the FDA-approved Guardant360® CDx provides comprehensive genomic results from a simple blood draw in seven days, helping them move beyond the limitations of tissue biopsies to match patients with the best treatments. Obtaining clinically relevant genomic information through a blood draw helps patients avoid an additional tissue or surgical biopsy and moves beyond the limitations of tissue specimens. Guardant360 CDx covers all genes recommended by the National Comprehensive Cancer Network, including the 55 genes most relevant to clinical care.
Guardant360 CDx is FDA approved for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), across all solid cancers and also as a companion diagnostic to identify non-small cell lung cancer patients who may benefit from treatment with Tagrisso® (osimertinib).
Since being introduced, the Guardant360 laboratory developed test (LDT) has become widely accepted for blood-based CGP with more than 200 peer-reviewed publications. It has been trusted by more than 9,000 oncologists, with more than 150,000 tests performed to date, and is broadly covered by Medicare and many private payers, representing over 200 million lives.
If you are a healthcare provider in the United States or Europe looking for information about Guardant360 CDx, please visit our product website. If you are a healthcare provider in Asia, Middle East, or Africa, please visit this website.